Cystic fibrosis medication causing antibiotic resistance

Abstract

Cystic fibrosis (CF) is a progressive, life-threatening condition that causes severe respiratory and digestive issues in addition to other consequences. It is an autosomal recessive genetic disease caused by the cystic fibrosis transmembrane regulator (CFTR). According to reports from the past ten years, CF is present in India, although its exact prevalence is unknown. In India, managing CF is challenging because to a lack of skilled personnel, a lack of availability, and the high cost of pharmacologic agents. Supplements, antibiotics, penicillin, and mucolytic agents are frequently employed as treatments, however this condition cannot be treated and occasionally even results in antibiotic resistance, which causes additional complications. Trikafta, the first triple combination therapy ever approved by the FDA, is being used to treat CF in patients 12 years of age and older who have the genetic mutation that afflict the great majority of CF patients which results in the decrease risk of antibiotic resistance. In the case of antibiotic resistance, even lung transplantation is significant.

Keywords: Cystic fibrosis, CFTR, Antibiotic resistance, Trikafta.